6GJ4 image
Deposition Date 2018-05-16
Release Date 2018-12-05
Last Version Date 2024-01-17
Entry Detail
PDB ID:
6GJ4
Keywords:
Title:
Tubulin-6j complex
Biological Source:
Source Organism:
Rattus norvegicus (Taxon ID: 10116)
Gallus gallus (Taxon ID: 9031)
Bos taurus (Taxon ID: 9913)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.40 Å
R-Value Free:
0.24
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Tubulin alpha-1B chain
Chain IDs:A, C
Chain Length:451
Number of Molecules:2
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Molecule:Tubulin beta-2B chain
Gene (Uniprot):TUBB2B
Chain IDs:B, D
Chain Length:445
Number of Molecules:2
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Molecule:Stathmin-4
Gene (Uniprot):Stmn4
Chain IDs:E
Chain Length:143
Number of Molecules:1
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Molecule:Tubulin tyrosine ligase
Chain IDs:F
Chain Length:384
Number of Molecules:1
Biological Source:Gallus gallus
Primary Citation

Abstact

Microtubule-targeting agents (MTAs) are a class of clinically successful anti-cancer drugs. The emergence of multidrug resistance to MTAs imposes the need for developing new MTAs endowed with diverse mechanistic properties. Benzoxazepines were recently identified as a novel class of MTAs. These anticancer agents were thoroughly characterized for their antitumor activity, although, their exact mechanism of action remained elusive. Combining chemical, biochemical, cellular, bioinformatics and structural efforts we developed improved pyrrolonaphthoxazepines antitumor agents and their mode of action at the molecular level was elucidated. Compound 6j, one of the most potent analogues, was confirmed by X-ray as a colchicine-site MTA. A comprehensive structural investigation was performed for a complete elucidation of the structure-activity relationships. Selected pyrrolonaphthoxazepines were evaluated for their effects on cell cycle, apoptosis and differentiation in a variety of cancer cells, including multidrug resistant cell lines. Our results define compound 6j as a potentially useful optimized hit for the development of effective compounds for treating drug-resistant tumors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures